Ashwagandha for menopause: what two 2025 clinical trials found

Ashwagandha for menopause: what two 2025 clinical trials found

A clinical trial published in Frontiers in Reproductive Health in January 2026 found that ashwagandha root extract reduced hot flash frequency, improved estradiol levels, and cut perceived stress scores in perimenopausal women within 56 days. None of the participants were on hormone therapy. The effect sizes were not small: the total menopause symptom score dropped across psychological, somatic, and urogenital domains compared to placebo (p < 0.0001 in each domain).

That result is not an outlier. A second trial published in the Journal of Menopausal Medicine in April 2025 found ashwagandha supplementation dose-dependently reduced menopausal quality-of-life scores, lowered inflammatory markers, cut bone resorption, and reduced vascular dysfunction in postmenopausal women over 24 weeks. The common thread in both studies is the same: a root used in Ayurvedic practice for more than 3,000 years is now clearing modern clinical standards for menopause support.

This article explains what ashwagandha does at a physiological level, why menopause creates the conditions that make it relevant, and what the combined evidence now supports for women navigating the transition.

What changes What ashwagandha addresses
HPA axis becomes harder to regulate as estrogen falls Ashwagandha's withanolides support the stress response, reducing excess cortisol output
Hot flashes intensify under psychological stress A 2026 RCT found significant reduction in hot flash frequency versus placebo within 56 days
Estradiol and progesterone decline throughout perimenopause The same RCT found improved serum estradiol and progesterone levels in the ashwagandha group (p < 0.001)
Anxiety and mood instability spike during the transition Perceived Stress Scale scores dropped significantly (p < 0.001) in the ashwagandha group
Bone resorption accelerates as estrogen deficiency deepens A 2025 trial found dose-dependent reduction in bone turnover markers with ashwagandha supplementation (p < 0.0001)


What happens to the stress response when estrogen declines

Estrogen does more than regulate the reproductive cycle. It keeps the hypothalamic-pituitary-adrenal (HPA) axis, the body's central stress management system, in a state of calibrated sensitivity. When estrogen is present in normal amounts, the feedback loop that shuts off cortisol after a stressor is fast and efficient. The stress response fires, does its job, and switches off.

As estrogen falls during perimenopause, that feedback mechanism weakens. The HPA axis becomes harder to brake. Cortisol levels stay elevated longer after a stressor. The nervous system stays in a state of low-level alertness it was not designed to maintain indefinitely. This is not a character trait or a sign of weakness. It is a hormonal consequence of the transition, and it explains why so many women describe perimenopause as a period of constant, inexplicable tension even when their external circumstances have not changed.

The relationship between estrogen and cortisol runs in both directions. Chronic elevated cortisol suppresses estrogen production, which further disrupts the feedback loop. The two hormones pull each other down in a cycle that can persist for years without targeted support.

Stage Estrogen level HPA axis behavior
Reproductive years Stable cyclical peaks Cortisol feedback loop intact; stress response resets efficiently
Early perimenopause Increasingly erratic Feedback loop begins to lag; cortisol clearance slows
Late perimenopause Steadily declining Prolonged cortisol elevation; sleep disrupted; mood unstable
Post-menopause Consistently low HPA hyperreactivity can persist without targeted support


Why perimenopausal women are more vulnerable to cortisol dysregulation

Hot flashes are not purely a thermoregulation problem. The hypothalamus, which controls body temperature, receives signals from both estrogen and the stress system. When estrogen falls, the temperature-regulating threshold in the hypothalamus narrows, meaning smaller temperature fluctuations trigger a flash. Psychological stress makes this worse. Cortisol signals the hypothalamus directly, and women who report higher perceived stress tend to experience more frequent and more intense flashes. This is why the same event, a deadline, an argument, a night of poor sleep, can trigger a flash in a perimenopausal woman that would not have happened five years earlier.

Mood instability follows a similar pattern. GABA, the brain's primary calming neurotransmitter, is sensitive to estrogen. Lower estrogen reduces GABAergic tone, which means the nervous system has less natural braking power. Anxiety rises not because life circumstances changed but because the underlying neurochemistry shifted. Adding a sustained cortisol load on top of already reduced GABAergic activity produces what many women describe as feeling "wired and exhausted at the same time."

Factor Mechanism Result for the woman
Estrogen loss HPA feedback loop weakens; cortisol lingers longer after a stressor Heightened baseline tension; difficulty winding down
Reduced GABA sensitivity Estrogen supports GABAergic activity; without it, calming signals weaken Anxiety, racing thoughts, poor sleep quality
Hypothalamic narrowing Temperature set-point becomes more sensitive; stress triggers thermal instability More frequent hot flashes during stressful periods
Cortisol-estrogen suppression Chronic cortisol suppresses adrenal conversion of estrogen precursors The stress cycle compounds the hormonal deficit


What the clinical evidence shows for ashwagandha in menopause

Ashwagandha (Withania somnifera) belongs to a class of herbs called adaptogens, which support the body's ability to manage physical and psychological stress. Its active compounds, called withanolides, act primarily on the HPA axis and on cortisol secretion pathways. This mechanism matters for menopause specifically because it targets the exact system that perimenopause dysregulates.

Clinical trial evidence: perimenopausal women

A 2026 randomized, double-blind, placebo-controlled trial published in Frontiers in Reproductive Health enrolled 60 women aged 45 to 55 years who received either ashwagandha root extract (ARE) or placebo for 56 days. The primary outcome, total Menopause Rating Scale (MRS) score, dropped significantly in the ARE group compared to placebo across all three domains: psychological (p < 0.0001), somatic (p < 0.0001), and urogenital (p < 0.0001). The ARE group also showed improved serum estradiol and progesterone, reduced FSH and LH, fewer hot flash events, lower perceived stress scores, and higher quality-of-life scores on the SF-12. All comparisons reached statistical significance (Vani, Muralidhar, and Rao, 2026).

Clinical trial evidence: postmenopausal women

A separate 2025 trial in the Journal of Menopausal Medicine enrolled postmenopausal women aged 40 to 55 in a 24-week double-blind design. Women receiving ashwagandha extract showed dose-dependent improvement in menopause-specific quality-of-life scores (MENQOL), reduced vascular dysfunction, lower bone resorption markers, and decreased systemic inflammation (C-reactive protein) and oxidative stress. All primary outcomes reached p < 0.0001 versus placebo (Pingali, Nutalapati, and Wang, 2025). The dose-dependent relationship indicates the effect is not coincidental.

Consistency across study populations

An earlier 2021 trial published in the Journal of Obstetrics and Gynaecology Research found ashwagandha root extract significantly reduced climacteric symptoms in perimenopausal women compared to placebo over eight weeks (Gopal et al., 2021). Three independent randomized controlled trials, across different populations, durations, and outcome measures, pointing in the same direction strengthens the evidence considerably.

What ashwagandha does not do

Ashwagandha is not a hormone. It does not replace estrogen or produce estrogenic effects in the body. What it does is support the body's ability to regulate cortisol and moderate the stress cascade that perimenopause worsens. This matters for women who are not candidates for hormone therapy or who are looking for support that does not carry hormonal risks.

Pro Tip: The clinical trials showing the strongest menopause-specific results used root extract standardized to withanolide content. When evaluating any ashwagandha supplement, look for "root extract" on the label rather than whole plant powder, and confirm the standardization percentage is listed.

How ashwagandha compares with other approaches

Women in perimenopause have several options for managing the anxiety and stress amplification that comes with hormonal change. Each works on a different part of the problem, which means the right choice depends on symptoms, health history, and what someone is willing to maintain long-term.

Approach How it works Considerations Best for
Ashwagandha Modulates HPA axis, reduces cortisol output, improves hormonal markers in clinical trials Not for use during pregnancy; confirm thyroid medication interactions with a prescriber Women who want HPA axis support without hormonal or pharmaceutical intervention
Menopausal hormone therapy (MHT) Replaces declining estrogen and progesterone directly Most effective for severe vasomotor symptoms; requires medical evaluation; not appropriate for all women Women with moderate to severe hot flashes or early menopause without contraindications
SSRIs and SNRIs Reduce anxiety and hot flash severity via serotonin and norepinephrine pathways Prescription required; sexual side effects and discontinuation effects are common concerns Women with co-occurring depression or anxiety disorders who cannot use MHT
Mindfulness and CBT Reduce reactivity to stress and perception of hot flash severity Useful for psychological symptoms; does not address the underlying hormonal disruption Women seeking behavioral tools alongside other interventions
Multi-ingredient botanical formula Addresses HPA axis, GABA pathways, and adrenal support simultaneously Effect depends on formulation quality and ingredient standardization Women who want non-hormonal support that targets multiple mechanisms

 

Ashwagandha and hormone therapy are not mutually exclusive. Some women use MHT for vasomotor symptoms while using adaptogenic support for residual anxiety and cortisol dysregulation that MHT alone does not fully address. The stress system remains disrupted even when estrogen is partially replaced, because cortisol dysregulation develops its own momentum over time.

One underappreciated consideration is duration. MHT requires ongoing prescriptions and medical monitoring. SSRIs carry discontinuation risk. Ashwagandha has a cleaner long-term safety profile at the doses studied, which matters for women who are looking at the next five to ten years, not just the next 90 days.

  • Consider professional evaluation if you experience:
  • Anxiety severe enough to interfere with work, relationships, or daily function
  • Panic attacks or persistent fear without an identifiable trigger
  • Hot flashes frequent enough to disrupt sleep more than three nights per week
  • Mood changes accompanied by hopelessness or loss of motivation
  • Any symptoms that worsen suddenly rather than following the gradual trajectory of perimenopause

How Botavive Tranquility supports the stressed nervous system during perimenopause

The challenge with managing perimenopause anxiety is that the problem is rarely one-dimensional. The HPA axis dysregulates, GABA tone drops, cortisol stays elevated, and sleep quality falls, which raises cortisol further. Each of these is a separate mechanism. A single-ingredient approach tends to address one piece while leaving the others unaddressed.

Botavive Tranquility combines ashwagandha root extract with Rhodiola rosea, L-Theanine, GABA, Magnesium Glycinate, and Vitamin B1. Ashwagandha works at the HPA axis level, reducing the overactive cortisol response that perimenopause amplifies. Rhodiola supports stress resilience through a different adaptogenic pathway and has clinical evidence for reducing fatigue associated with prolonged stress. L-Theanine promotes alpha-wave brain activity, supporting calm focus without sedation. GABA addresses the inhibitory neurotransmitter system that estrogen loss weakens. Magnesium Glycinate supports a common deficiency that worsens under chronic cortisol elevation and plays a direct role in nervous system regulation. Vitamin B1 supports the adrenal function that the stress response depends on.

Tranquility is not a treatment for perimenopause or a substitute for medical care. It is a non-hormonal supplement built around ingredients with clinical support for the specific mechanisms that hormonal change disrupts. For women who are not candidates for MHT, or who want additional support alongside it, it addresses the cortisol and anxiety pattern that menopause creates.

Frequently asked questions

How does ashwagandha reduce hot flashes if it is not a hormone?

Hot flashes are triggered partly by the hypothalamus, which regulates body temperature and is sensitive to both estrogen and cortisol. Ashwagandha reduces cortisol output, which removes one of the triggers that activates the hypothalamic temperature reset. The 2026 Frontiers trial measured hot flash frequency directly and found a statistically significant reduction in the ashwagandha group versus placebo within 56 days, which supports this mechanism.

How long does it take to notice a difference from ashwagandha?

The 56-day Frontiers trial measured significant improvement at the end of the study period. The 24-week Journal of Menopausal Medicine trial showed dose-dependent results over six months. Most clinical protocols for adaptogenic herbs use 8-to-12-week minimum periods before drawing conclusions. Adaptogens recalibrate the stress axis over time rather than producing an acute effect like a sleep aid or pain reliever.

Can ashwagandha replace hormone therapy?

No. For women with moderate to severe vasomotor symptoms or who are at elevated risk from estrogen deficiency, hormone therapy remains the most effective intervention with the deepest body of safety data. Ashwagandha addresses the cortisol and stress axis disruption that menopause creates. It is one component of a broader strategy, not a substitute for medical evaluation.

Is ashwagandha safe to take long-term during perimenopause?

The safety data from clinical trials at standard doses is reassuring. The 2026 Frontiers trial measured adverse events across its full 56-day period and found the extract well tolerated. The 2025 Journal of Menopausal Medicine trial ran 24 weeks with similar findings. Women taking thyroid medication should discuss potential interactions with their prescriber, as ashwagandha may influence thyroid hormone levels in some individuals.

Is perimenopause anxiety different from clinical anxiety?

Perimenopause anxiety tends to feel different because it is neurochemical in origin rather than driven by identifiable life circumstances. Women who have had no prior anxiety history describe it as new and disorienting: tension without a clear cause, racing thoughts in the early hours, or an inability to wind down that does not respond to usual strategies. The underlying difference is that the GABA and cortisol systems are dysregulated, not that thought patterns are the problem. This is why behavioral approaches alone often do not resolve it, and why HPA axis support tends to be a more direct intervention.

Sources

  1. Vani I, Muralidhar G, Rao BS. A prospective, randomized, double-blind, placebo-controlled study on efficacy and safety of Ashwagandha root extract (Withania somnifera) for managing menopausal symptoms in women. Front Reprod Health. 2026 Jan 5;7:1647721. doi: 10.3389/frph.2025.1647721. https://www.frontiersin.org/journals/reproductive-health/articles/10.3389/frph.2025.1647721/full
  2. Pingali U, Nutalapati C, Wang Y. Ashwagandha and Shatavari Extracts Dose-Dependently Reduce Menopause Symptoms, Vascular Dysfunction, and Bone Resorption in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Study. J Menopausal Med. 2025 Apr;31(1):21-34. doi: 10.6118/jmm.24025. https://pubmed.ncbi.nlm.nih.gov/40347163/
  3. Gopal S, Ajgaonkar A, Kanchi P, et al. Effect of an ashwagandha (Withania somnifera) root extract on climacteric symptoms in women during perimenopause: A randomized, double-blind, placebo-controlled study. J Obstet Gynaecol Res. 2021 Dec;47(12):4414-4425. doi: 10.1111/jog.15030. https://pubmed.ncbi.nlm.nih.gov/34553463/

Related articles

Previous post Next post
Back to blog